Related Experiment Videos
Perindopril: possible use in cancer therapy
Hitoshi Yoshiji1, Shigeki Kuriyama, Hiroshi Fukui
1Third Department of Internal Medicine, Nara Medical University, Shijo-cho 840, Kashihara, Nara 634-8522, Japan. yoshijih@naramed-u.ac.jp
Anti-Cancer Drugs
|May 2, 2002
Summary
Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, effectively inhibits tumor growth and angiogenesis by suppressing vascular endothelial growth factor (VEGF). This widely used drug shows promise as a novel anticancer therapy due to its safety profile.
Area of Science:
- Oncology
- Pharmacology
- Cardiovascular Research
Background:
- Angiogenesis is crucial for solid tumor growth, driving the need for antiangiogenic therapies.
- Currently, no antiangiogenic agents are widely available for clinical use.
- Angiotensin-converting enzyme (ACE) inhibitors, used for hypertension, may reduce cancer risk.
Purpose of the Study:
- To investigate the antiangiogenic and antitumor effects of the ACE inhibitor perindopril.
- To determine if perindopril affects vascular endothelial growth factor (VEGF) levels and activity.
- To evaluate the potential of perindopril as an anticancer therapeutic strategy.
Main Methods:
- Experimental tumor development and angiogenesis models were used.
- In vitro studies assessed cytotoxicity to tumor and endothelial cells.
- Vascular endothelial growth factor (VEGF) levels and VEGF-induced tumor growth were analyzed.
Main Results:
- Perindopril demonstrated potent inhibition of experimental tumor development and angiogenesis at clinically relevant doses.
- Perindopril significantly suppressed vascular endothelial growth factor (VEGF).
- Perindopril did not exhibit cytotoxicity to tumor or endothelial cells in vitro.
Conclusions:
- Perindopril exhibits significant antiangiogenic and antitumor properties.
- Suppression of VEGF by perindopril contributes to its observed anticancer effects.
- Given its established safety profile, perindopril represents a potential new strategy for anticancer therapy.